Immuron (IMRN) Gross Margin (2016 - 2024)
Immuron (IMRN) posted quarterly Gross Margin of 21833218650105.83% for Q4 2024, down 2183321865017292.2% year-on-year from N/an in Q1 2024, and down 32543397522554.73% on a QoQ basis from 67.09% in Q4 2023.
Immuron (IMRN) Gross Margin (2016 - 2024) Analysis & Trends
Immuron (IMRN) has reported Gross Margin for 9 consecutive years, with 21833218650105.83% the latest figure, recorded in Q4 2024.
- Quarterly Gross Margin fell 2183321865017292.2% year-over-year to 21833218650105.83% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 16146642179790.97% (down 1614664221753085.0% YoY) and the FY2025 annual result came in at 65.39%, down 267.0% from the prior year.
- Gross Margin eased to 21833218650105.83% in Q4 2024 per IMRN's latest filing, from 67.09% in the prior quarter.
- Over the last five years, Gross Margin for IMRN reached as high as 69943800.77% in Q4 2021 and fell as low as 21833218650105.83% in Q4 2024.
- A 5-year average of 3638851696061.0% and a median of 78.03% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2020 — Gross Margin jumped 2000000000 bps — and 2024, when it sank 2000000000 bps.
- Year by year, Gross Margin stood at 38529715.89% in 2020, then soared by 82 bps to 69943800.77% in 2021, then sank by 100 bps to 73.32% in 2022, then declined by 8 bps to 67.09% in 2023, then sank by 2000000000 bps to 21833218650105.83% in 2024.
- According to Business Quant data, Gross Margin over the past three periods registered 21833218650105.83%, 67.09%, and 82.75% for Q4 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -21,833,218,650,105.83% |
| Dec 31, 2023 | 67.09% |
| Jun 30, 2023 | 82.75% |
| Dec 31, 2022 | 73.32% |
| Dec 31, 2021 | 69,943,800.77% |
| Dec 31, 2020 | 38,529,715.89% |
| Dec 31, 2019 | 0.47% |
| Dec 31, 2018 | 76.34% |
| Dec 31, 2017 | 78.75% |
| Dec 31, 2016 | 68.23% |
| Jun 30, 2016 | 73.91% |